Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2015—Microbiologics has entered into an agreement to source inactivated viruses from Microbix Biosystems. Microbiologics will incorporate these inactivated materials into a line of full process controls under its Helix Elite Molecular Standards brand as well as instrument-specific quality control sets.
June 2015—Thermo Fisher Scientific announced the release of the CE-IVD Oncomine Solid Tumour Fusion Transcript kit designed to aid clinical decision-making and enable highly accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor samples.
June 2015—Enzo Biochem announced the development of the FlowScript assay in detection of messenger RNA from HPV oncogenes E6 and E7. The FlowScript technology platform is a proprietary flow-cytometry-based molecular detection system for the multiplex analysis of cell function and identity; the HPV E6/E7 assay is the first product to use this novel platform.
June 2015—The U.S. Patent and Trademark Office awarded a third U.S. patent to BioDot for its FISHArray technology and methods. BioDot’s patent family broadly covers technology and methods for performing multiple fluoresence in situ hybridization, immunohistochemistry, and cytogenetic tests on a single substrate, whether performed manually or through automated workstations, such as the company’s CellWriter Workstation.
June 2015—Oxford Immunotec announced the availability in the United States of a test that measures the strength of a patient’s cellular immune response to cytomegalovirus. The T-Spot.CMV test is available as a laboratory-developed test from the company’s CLIA-certified and CAP-accredited service laboratory.
June 2015—The Clinical and Laboratory Standards Institute has published a new document, “Process Management (QMS18-Ed1).” The guideline defines four requirements for managing laboratory processes and provides suggestions for meeting regulatory and accreditation requirements …
June 2015—Dako, an Agilent Technologies Company, announced a new master collaboration agreement with Amgen. The expanded collaboration will allow both companies to benefit from knowledge sharing within the field of drug-diagnostic research and development and in relation to companion diagnostic products.
June 2015—APiQ (Anatomic Pathology with Extra Intelligence) from Leica provides real-time laboratory workflow information on mobile devices. The initial release consists of two immunohistochemistry solutions: the APiQ Inventory Manager and the APiQ Instrument Dashboard.
June 2015—Horizon Discovery Group has signed a supply and commercialization agreement with Thermo Fisher Scientific. Under the terms of the agreement, Thermo Fisher will market and distribute Horizon’s X-MAN human haploid and diploid isogenic cell line collection and will further offer the X-MAN haploid cell line generation service to its worldwide customer base.
June 2015—Agena Bioscience released the LungFusion Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. Using as little as 10 ng of complementary DNA template, the research-use-only, single-well panel identifies expressed translocations of known clinical relevance in formalin-fixed, paraffin-embedded and fresh frozen tissue samples.
